PMcardio receives FDA Breakthrough Device Designation — read the full story
Powerful Medical
17. September 2024
5 min to read

Performance of Artificial Intelligence Powered ECG Analysis in Suspected ST-Segment Elevation Myocardial Infarction

Overview:

In one of the largest US regional STEMI care networks, the Midwest STEMI Consortium, the PMcardio STEMI AI Model accurately identified 89% of patients needing urgent management while reducing unnecessary catheterizations by 28%. AI-powered standardized ECG interpretation may optmize STEMI triage by reducing costly, unwarranted cath lab activations while ensuring precise and timely diagnosis.

Presented at: American College of Cardiology (ACC) 2024 Quality Summit
Presented Date: September 17, 2024

Background

In patients with symptoms of acute myocardial ischemia, electrocardiographic ST-segment elevation (STE) is a reliable noninvasive indicator of total or subtotal acute coronary artery occlusion.

Consequently, the electrocardiogram (ECG) plays a fundamental role in the diagnosis of ST-elevation myocardial infarction (STEMI) and serves as a “gatekeeper,” where the presence of STE triggers cardiac catheterization laboratory activation to provide emergent coronary artery revascularization. However, this ECG-based triage approach is imperfect. ECG interpretation for suspected acute myocardial infarction is not standardized, and there is considerable variability in interpretation skills among healthcare providers.

Furthermore, ECG patterns other than STE are now recognized as markers for acute coronary artery occlusion (STEMI equivalents). These STEMI-equivalent patterns, which include changes in T-wave amplitude and area, are unfamiliar to many providers and may be better suited for computerized analysis.

Given these challenges and the continued importance of ECG in STEMI management, artificial intelligence (AI)-powered ECG analysis has demonstrated potential for improving diagnosis, reducing variability in ECG interpretation, and ultimately leading to better patient outcomes.

Methods

Patients were gathered from the Midwest STEMI Consortium (2018–2022), which included three high-volume STEMI-PCI centers: Minneapolis Heart Institute (Minneapolis, MN), Prairie Cardiovascular Institute (Springfield, IL), and The Christ Hospital (Cincinnati, OH). Cardiac catheterization laboratory-activating ECGs (aECGs) from consecutive patients with suspected STEMI were analyzed.

Acute myocardial infarction (AMI) was defined as troponin elevation above the 99th percentile. Patients were categorized into three groups: AMI with a culprit lesion (AMI culprit), AMI without a culprit lesion (AMI no culprit), and no AMI.

The ECGs were digitized and blindly analyzed using the Powerful Medical PMcardio AI ECG platform, classifying each ECG as occlusion myocardial infarction (OMI) or not OMI. PMcardio is a CE-certified clinical care coordination platform that enables healthcare professionals at the first point of contact to detect cardiovascular disease using artificial intelligence-powered electrocardiograms.

The performance of the AI-ECG classification (OMI vs. not OMI) was compared across the three clinical categories: AMI with culprit, AMI without culprit, and no AMI.

Results

The AI-ECG model demonstrated strong performance in identifying culprit artery occlusion in suspected STEMI cases. It classified 94% of acute MI with culprit lesions as occlusion MI, compared to 67% in acute MI without culprit and 60% in no acute MI (p < 0.001). The model’s predictions correlated with key clinical indicators, including peak troponin (20 vs. 4 vs. 0 ng/mL, p < 0.001) and 30-day mortality (6.6% vs. 11% vs. 3.3%, p = 0.004).

Value Proposition

An accurate AI-powered ECG interpretation for patients with suspected acute myocardial infarction could significantly enhance patient evaluation and management in several ways:

  1. Standardized identification of patients who require emergent revascularization for acute coronary artery occlusion, overcoming variability in individual ECG interpretation skills.
  2. Reduction in time to treatment, leading to improved patient outcomes.
  3. Decreased unnecessary emergent cardiac catheterization laboratory activations, resulting in economic benefits.
  4. Improved accessibility across diverse healthcare settings, including rural, urban, inpatient, outpatient, and both in-person and virtual environments.
  5. An effective quality improvement tool, capable of automatic benchmarking.
  6. Potential for continuous self-improvement with each use, making it a dynamic platform.

“Ultimately, this advancement could result in a new paradigm for ECG interpretation in suspected acute myocardial infarction with global benefits.” (authors)

Authors: S. Sharkey, R. Herman, D. Larson, T. Henry, F. Aguirre, A. Murthy, H. Rohm, S. Smith, M. Yildiz, W. Belzer, J. Chambers, S. Bergstedt, G. Kerola, D. Farmer, A. Willett, J. Bartunek, P. Meyers, E. Barbato, J. Harris, D. Witt

Author-Logo_PM
Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.

About PMcardio

PMcardio is a CE-certified AI that reads ECGs and offers a complex assessment of 49 cardiac conditions. Clinically validated in 15+ studies and trusted by over 100,000 clinicians, it delivers rapid, expert‑level interpretations, empowering emergency physicians, GPs, nurses, paramedics, and cardiologists to act with confidence at the point of care. Available for Individuals and Organizations.

About Powerful Medical

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Relevant Publications

Validation of an artificial intelligence ECG model for detection of acute coronary occlusion myocardial infarction in unselected emergency department chest pain patients

Across 24 513 consecutive chest-pain presentations to five Swedish emergency departments, the Queen of Hearts (QoH) AI-ECG model detected acute coronary occlusion myocardial infarction with 52 % sensitivity and 99 % specificity. It outperformed an extended STEMI algorithm applied to the same cohort (41 % sensitivity, 95 % specificity) and more than doubled the sensitivity of classic STEMI criteria (55 % versus 26 %) while preserving comparable specificity (99 % versus 98 %). This real-world validation demonstrates that QoH markedly improves early ECG recognition of OMI in unselected, non-traumatic chest-pain patients.

Artificial Intelligence Based Detection of Acute Coronary Occlusion Compared to STEMI Criteria – External Validation Study in a Consecutive All-Comer German Chest Pain Unit Cohort

2nd place - DGK Young Investigator Awards 2025, Germany: In a real-world cohort of over 4,000 chest pain patients presenting to a German CPU, excluding obvious STEMI heart attacks diagnosed before arrival, an AI ECG model detected serious artery blockages (ACO) with 97.8% accuracy. It outperformed traditional STEMI criteria, achieving higher sensitivity (70.2% vs 28.8%) and fewer false positives.

Join over 100,000 healthcare professionals who are already taking advantage of AI